Solid Lipid Nanoparticles: Fundamentals, Design and Applications
Chapter 9 - Intravenous Delivery of SLNs: A Nanocarrier Approach for Optimized Therapeutics
G. Naveena, Valleti. Lakshmipriyanka, Y. Sarah Sujitha
Abstract:
A promising nanocarrier system for the delivery of therapeutic agents, particularly through the intravenous (IV) route, is solid lipid nanoparticles (SLNs). They are a desirable platform for targeted and regulated drug delivery because of their distinct physicochemical characteristics, biocompatibility, and capacity to improve drug solubility and bioavailability. In addition to discussing formulation strategies and assessing their performance in preclinical and clinical studies, this review highlights the benefits of SLNs in IV drug administration. Issues pertaining to their growth and prospects for the future are also discussed.
Keywords: Administration, Bioavailability, Biocompatibility, Clinical studies, Distribution, Intravenous, Lipophilic, Nanoparticles, Physicochemical, Solubility, Solid lipid nanoparticles.
References:
[1] Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
[2] Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–1272.
[3] Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64(Suppl):83–101.
[4] Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–358.
[5] Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59(6):478–490.
[6] Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2(1):80–102.
[7] Hu FQ, Jiang SP, Du YZ, Yuan H, Ye Y, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm. 2006;314(1):83–89.
[8] Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): method, characterization and applications. Int Curr Pharm J. 2012;1(11):384–393.
[9] Gohla SH, Schneider M. Lipid nanoparticles for topical and transdermal drug delivery. Drug Dev Ind Pharm. 2010;36(3):292–298.
[10] Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149–155.
[11] Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161–172.
[12] Shah R, Eldridge D, Palombo E, Harding I. Composition and structure of lipid nanoparticles: A review. Chem Phys Lipids. 2014;181:1–10.
[13] Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull. 2006;29(9):1790–1798.
[14] Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm. 2003;29(9):1013–1026.
[15] Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889–4906.
[16] Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491– 504.
[17] Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289–300.
[18] Cavalli R, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int J Pharm. 1999;182(1):59–69.
[19] Reddy LH, Murthy RS. Etoposide-loaded solid lipid nanoparticles: formulation, development, physical characterization, and in vitro and in vivo evaluation. Pharm Dev Technol. 2005;10(4):495–503.
[20] Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles – evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125–131.
[21] Dolatabadi JEN, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv Pharm Bull. 2015;5(2):151– 159.
[22] Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–161.
[23] Silva AC, González-Mira E, García ML, Egea MA, Fonseca J, Silva R, Santos D, Souto EB. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces. 2011;86(1):158–165.
[24] Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) vs nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633–640.
[25] Puglia C, Offerta A, Carbone C, Bonina F, Pignatello R, Bucolo C. Lipid nanoparticles as novel delivery systems for ophthalmic applications. J Drug Deliv Sci Technol. 2015;30:303–312.
[26] Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development & industrial applications. Curr Drug Discov Technol. 2011;8(3):207–227.
[27] Rainer H, Friedrich F, Derendorf H. Clinical pharmacokinetics of anticancer drugs. Ther Drug Monit. 1996;18(2):133–140.
[28] Joshi M, Patravale V. FormulHelgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. Effect of surfactant surface coverage on the formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci 2009;334:75-81.
[29] Formulation and evaluation of nanostructured lipid carrier (NLC)–based gel for topical delivery of aceclofenac. Curr Drug Deliv. 2013;10(5):627– 632.
[30] Kumar R, Kaur R, Sharma G, Mehta SK. Development and evaluation of solid lipid nanoparticles for the topical delivery of an anti-acne drug: a novel approach. Indian J Pharm Sci. 2016;78(1):65–73.
[31] Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875–880.
[32] Loxley A. Solid lipid nanoparticles for the delivery of pharmaceutical actives. Drug Deliv Technol 2009;9 Suppl 8:32.
[33] Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. Effect of surfactant surface coverage on the formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci 2009;334:75-81.
[34] Jawahar N, Meyyanathan SN, Reddy G, Sood S. ChemInform abstract: solid lipid nanoparticles for oral delivery of poorly soluble drugs. ChemInform. 2013.
[35] Luo WC, Lu X. Solid lipid nanoparticles for drug delivery. Methods Mol Biol. 2023;2622:139–46.
[36] Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsificationdiffusion technique. Int J Pharm 2003;257(1-2): 153-60.
[37] Schubert MA, Muller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm2005;61:77-86.
[38] Sinha VR, Srivastava S, Goel H, Jindal V. Solid lipid nanoparticles (SLN’s) – trends and implications in drug targeting. Int J Adv Pharmaceut Sci 2010;1:212-238.
[39] Thukral DK, Dumoga S, Mishra AK. Solid lipid nanoparticles: promising therapeutic nanocarriers for drug delivery. Curr Drug Deliv. 2014;11(6):771-91
[40] Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A Recent Update: Solid Lipid Nanoparticles for Effective Drug Delivery. Adv Pharm Bull. 2022 Jan;12(1):17-33.